Alkermes price target raised to $40 from $35 at Mizuho
The Fly

Alkermes price target raised to $40 from $35 at Mizuho

Mizuho raised the firm’s price target on Alkermes (ALKS) to $40 from $35 and keeps an Outperform rating on the shares. The firm assessed its forecast and conducted a sum-of-the-parts analysis. The investor debate is shifting towards ALKS 2680, which will gain greater attention into the Phase 2 readouts in the second half of 2025, given its potential to be disruptive in the $10B branded narcolepsy and idiopathic hypersomnia markets, the analyst tells investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App